Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction.

Abstract

Recent human and animal studies have shown a possible role for calcitonin gene-related peptide in penile erection and a therapeutic benefit in combination with prostaglandin E1 for autoinjection therapy. The ethical committee approved calcitonin gene-related peptide-prostaglandin E1 combination for cases of nonresponse or cavernous fibrosis to papaverine-phentolamine. Since June 1990, 65 patients (59 nonresponders and 6 with fibrosis) were injected with 5 micrograms. calcitonin gene-related peptide plus 10 micrograms. prostaglandin E1. Of the 59 nonresponders to papaverine-phentolamine 31 and of the 6 patients with fibrosis 5 had full erectile response. Of these 36 patients 2 experienced pain during the pharmacologically induced erection. A total of 39 patients who had had at least 20 autoinjections of calcitonin gene-related peptide plus prostaglandin E1 was available for minimum followup. There were no side effects, such as pain (the 2 patients with pain mentioned previously were not included in the autoinjection therapy group), systemic side effects or (increased) fibrosis. Our results show that a combination of calcitonin gene-related peptide and prostaglandin E1 may be beneficial to the treatment of impotence in carefully selected patients.

• Authors: M Djamilian, C G Stief, M Kuczyk, U Jonas
• Journal: The Journal of urology (J Urol) Vol. 149 Issue 5 Pt 2 Pg. 1296-8 (May 1993) ISSN: 0022-5347 [Print] United States
• PMID: 8479019 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Alprostadil
• Calcitonin Gene-Related Peptide

Topics

• Alprostadil (pharmacology, therapeutic use)
• Calcitonin Gene-Related Peptide (pharmacology, therapeutic use)
• Drug Therapy, Combination
• Erectile Dysfunction (drug therapy)
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Penile Erection (drug effects)
• Self Administration